Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SRS001
MIFTS: 54

Serous Cystadenocarcinoma

Categories: Cancer diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Serous Cystadenocarcinoma

About this section

MalaCards integrated aliases for Serous Cystadenocarcinoma:

Name: Serous Cystadenocarcinoma 12 15
Cystadenocarcinoma, Serous 44 73
Cystadenocarcinoma Serous 55
Serous Adenocarcinoma 12
Serous Carcinoma 12

Classifications:

MalaCards categories:
Global: Cancer diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:3114
MeSH 44 D018284
NCIt 50 C3778 C40101
SNOMED-CT 68 189685001 90725004
UMLS 73 C0206701
Sources

Summaries for Serous Cystadenocarcinoma

About this section
Disease Ontology : 12 A cystadenocarcinoma that derives from epithelial cells originating in glandular tissue forming serous lesions.

MalaCards based summary : Serous Cystadenocarcinoma, also known as cystadenocarcinoma, serous, is related to uterine corpus serous adenocarcinoma and primary peritoneal carcinoma. An important gene associated with Serous Cystadenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Innate Immune System and GPCR Pathway. The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include ovary, pancreas and liver, and related phenotypes are Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance and Increased cell death HMECs cells

Wikipedia : 76 Serous cystadenocarcinoma is a type of tumor in the cystadenocarcinoma grouping. Most commonly the... more...

Sources

Related Diseases for Serous Cystadenocarcinoma

About this section

Diseases related to Serous Cystadenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 162)
# Related Disease Score Top Affiliating Genes
1 uterine corpus serous adenocarcinoma 33.2 ERBB2 TP53
2 primary peritoneal carcinoma 31.5 ERBB2 MUC16 PGR TP53 VEGFA
3 ovarian serous cystadenocarcinoma 29.4 B2M ERBB2 FBXW7 HRAS MUC16 PATL2
4 endometriosis 29.1 ESR2 PGR VEGFA
5 cystadenocarcinoma 26.4 AKT1 ERBB2 ESR2 FBXW7 HRAS MUC16
6 ovarian cancer 23.6 AKT1 ALPP ERBB2 ESR2 MMP14 MMP2
7 pancreatic serous cystadenocarcinoma 12.3
8 ovarian serous carcinoma 12.1
9 ovary serous adenocarcinoma 11.3
10 papillary serous adenocarcinoma 11.1
11 adult hepatocellular carcinoma 10.9 PIK3CA TP53
12 malignant spiradenoma 10.9 PIK3CA TP53
13 gallbladder squamous cell carcinoma 10.8 ERBB2 TP53
14 gastric papillary adenocarcinoma 10.8 ERBB2 TP53
15 apocrine adenoma 10.8 HRAS PIK3CA
16 endometrium carcinoma in situ 10.8 PGR TP53
17 prostate adenoid cystic carcinoma 10.7 HRAS PIK3CA
18 vestibular gland benign neoplasm 10.7 PGR TP53
19 bartholin's gland adenoma 10.7 PGR TP53
20 spitz nevus 10.6 HRAS TP53
21 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 10.6 PIK3CA PPP2R1A TP53
22 scirrhous adenocarcinoma 10.6 ERBB2 PGR
23 ovarian clear cell carcinoma 10.6 PIK3CA PPP2R1A TP53
24 breast apocrine carcinoma 10.6 ERBB2 PGR
25 female reproductive endometrioid cancer 10.6 PGR TP53
26 epithelial-myoepithelial carcinoma 10.6 FBXW7 HRAS TP53
27 breast malignant phyllodes tumor 10.6 PGR TP53
28 esophagus adenocarcinoma 10.6 ERBB2 PIK3CA TP53
29 glassy cell carcinoma of the cervix 10.6 ERBB2 PGR
30 lung adenoid cystic carcinoma 10.6 FBXW7 HRAS PIK3CA
31 olfactory groove meningioma 10.6 PGR TP53
32 non-proliferative fibrocystic change of the breast 10.6 ERBB2 TP53
33 breast mucoepidermoid carcinoma 10.6 ERBB2 PGR
34 meningeal melanomatosis 10.6 B2M HRAS TP53
35 bladder squamous cell carcinoma 10.6 ERBB2 PIK3CA TP53
36 breast metaplastic carcinoma 10.5 ERBB2 PGR
37 intracystic papillary adenoma 10.5 ERBB2 PGR
38 aggressive digital papillary adenocarcinoma 10.5 HRAS PIK3CA
39 progesterone-receptor negative breast cancer 10.5 ERBB2 PGR
40 breast medullary carcinoma 10.5 ERBB2 PGR
41 ovary adenocarcinoma 10.5 ERBB2 HRAS TP53
42 rare adenocarcinoma of the breast 10.5 AKT1 PIK3CA TP53
43 breast scirrhous carcinoma 10.5 ERBB2 PGR
44 acneiform dermatitis 10.5 ERBB2 HRAS PIK3CA
45 anal squamous cell carcinoma 10.5 AKT1 PIK3CA TP53
46 adenosquamous cell lung carcinoma 10.4 ERBB2 HRAS PIK3CA
47 ethmoid sinus cancer 10.4 HRAS PIK3CA
48 pilocytic astrocytoma 10.4 HRAS PIK3CA TP53
49 adenoid basal cell carcinoma 10.4 B2M PGR
50 oncocytic breast carcinoma 10.4 ERBB2 PGR

Graphical network of the top 20 diseases related to Serous Cystadenocarcinoma:



Diseases related to Serous Cystadenocarcinoma
Sources

Symptoms & Phenotypes for Serous Cystadenocarcinoma

About this section

GenomeRNAi Phenotypes related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.35 ALPP ERBB2 HRAS PPP2R1A VEGFA
2 Increased cell death HMECs cells GR00103-A-0 9.02 FBXW7 PGR PIK3CA PPP2R1A TP53

MGI Mouse Phenotypes related to Serous Cystadenocarcinoma:

46 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.38 PGR MMP2 PIK3CA VEGFA TP53 ESR2
2 homeostasis/metabolism MP:0005376 10.34 PGR MMP2 PIK3CA PPP2R1A VEGFA TP53
3 growth/size/body region MP:0005378 10.33 MMP2 PIK3CA PPP2R1A VEGFA TP53 B2M
4 behavior/neurological MP:0005386 10.3 MMP14 PGR PIK3CA PPP2R1A VEGFA TP53
5 endocrine/exocrine gland MP:0005379 10.3 PGR PIK3CA VEGFA TP53 ESR2 AKT1
6 cellular MP:0005384 10.29 PIK3CA MMP14 PGR TP53 VEGFA B2M
7 mortality/aging MP:0010768 10.27 PGR MMP2 PIK3CA PPP2R1A VEGFA TP53
8 integument MP:0010771 10.24 PGR PIK3CA VEGFA TP53 AKT1 ERBB2
9 immune system MP:0005387 10.21 PIK3CA MMP14 PGR MMP2 VEGFA TP53
10 hematopoietic system MP:0005397 10.19 MMP14 PGR MMP2 TP53 VEGFA B2M
11 digestive/alimentary MP:0005381 10.18 VEGFA TP53 B2M ERBB2 MMP14 ESR2
12 neoplasm MP:0002006 10.18 MMP2 PIK3CA PGR VEGFA PPP2R1A TP53
13 embryo MP:0005380 10.17 MMP14 PGR PIK3CA VEGFA TP53 AKT1
14 craniofacial MP:0005382 10.13 MMP14 MMP2 VEGFA TP53 ERBB2 FBXW7
15 nervous system MP:0003631 10.11 MMP14 MMP2 PIK3CA VEGFA TP53 B2M
16 muscle MP:0005369 10.09 PGR MMP2 PIK3CA VEGFA TP53 AKT1
17 normal MP:0002873 10 PGR MMP2 PPP2R1A VEGFA TP53 ESR2
18 limbs/digits/tail MP:0005371 9.95 MMP14 PGR TP53 VEGFA ERBB2 ESR2
19 no phenotypic analysis MP:0003012 9.87 PIK3CA MMP14 PGR VEGFA TP53 ESR2
20 reproductive system MP:0005389 9.81 MMP14 PGR PIK3CA VEGFA TP53 B2M
21 respiratory system MP:0005388 9.61 MMP2 VEGFA TP53 ESR2 AKT1 ERBB2
22 skeleton MP:0005390 9.32 PGR MMP2 PIK3CA VEGFA TP53 AKT1
Sources

Drugs & Therapeutics for Serous Cystadenocarcinoma

About this section

Drugs for Serous Cystadenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 192)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
3
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
4
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
5
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
6
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
7
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
8
Epirubicin Approved Phase 3 56420-45-2 41867
9
Everolimus Approved Phase 2, Phase 3,Phase 1 159351-69-6 6442177
10
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
11
Sirolimus Approved, Investigational Phase 2, Phase 3,Phase 1 53123-88-9 5284616 6436030 46835353
12
Topotecan Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 119413-54-6, 123948-87-8 60700
13
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
14
Letrozole Approved, Investigational Phase 2, Phase 3,Phase 3,Early Phase 1 112809-51-5 3902
15
Gemcitabine Approved Phase 3,Phase 1,Phase 2 95058-81-4 60750
16
Metformin Approved Phase 2, Phase 3,Phase 1,Early Phase 1 657-24-9 14219 4091
17
Olaparib Approved Phase 2, Phase 3,Phase 1,Early Phase 1 763113-22-0 23725625
18
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
19
Trametinib Approved Phase 2, Phase 3,Phase 1 871700-17-3 11707110
20
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
21
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 1 56-86-0 33032
22
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
23
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Not Applicable 59-30-3 6037
24
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
25
Cediranib Investigational Phase 2, Phase 3,Phase 1 288383-20-0 9933475
26
Maleic acid Experimental Phase 2, Phase 3,Phase 1 110-16-7 444266
27 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
28 Antimitotic Agents Phase 3,Phase 2,Phase 1
29 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
30 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
31 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
32 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
33 Hormones Phase 2, Phase 3,Phase 3,Early Phase 1,Not Applicable
34 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
35 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
36 Antibodies Phase 3,Phase 2,Phase 1
37 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
38 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
39 Immunoglobulin G Phase 3,Phase 2,Phase 1
40 Immunoglobulins Phase 3,Phase 2,Phase 1
41 Mitogens Phase 3,Phase 2,Phase 1
42 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
43 Antifungal Agents Phase 2, Phase 3,Phase 1
44 Anti-Infective Agents Phase 2, Phase 3,Phase 3,Phase 1
45 Hormone Antagonists Phase 2, Phase 3,Phase 3,Early Phase 1,Not Applicable
46 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3,Phase 3,Early Phase 1,Not Applicable
47 Immunosuppressive Agents Phase 2, Phase 3,Phase 3,Phase 1
48 Antineoplastic Agents, Hormonal Phase 2, Phase 3,Not Applicable
49 Protein Kinase Inhibitors Phase 2, Phase 3,Phase 3,Phase 1
50 topoisomerase I inhibitors Phase 2, Phase 3,Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 163)
# Name Status NCT ID Phase Drugs
1 Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer Completed NCT00003749 Phase 3
2 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
3 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
4 Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer Completed NCT00005583 Phase 3 cisplatin;doxorubicin hydrochloride;epirubicin hydrochloride
5 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3 cisplatin;paclitaxel
6 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
7 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3 cisplatin;paclitaxel
8 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3 cisplatin;paclitaxel
9 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3 carboplatin;paclitaxel
10 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3 cisplatin;doxorubicin hydrochloride
11 Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer Completed NCT00006027 Phase 3 cisplatin;paclitaxel
12 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
13 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
14 Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
15 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
16 Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Active, not recruiting NCT03285802 Phase 2, Phase 3 Letrozole;Everolimus
17 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Active, not recruiting NCT02101788 Phase 2, Phase 3 Letrozole;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Tamoxifen Citrate;Topotecan Hydrochloride;Trametinib
18 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
19 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
20 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
21 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
22 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
23 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
24 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
25 Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Active, not recruiting NCT01672892 Phase 3
26 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Suspended NCT02502266 Phase 2, Phase 3 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
27 Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer Terminated NCT00003880 Phase 2, Phase 3 carboplatin;paclitaxel
28 Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
29 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
30 Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer Unknown status NCT02112552 Phase 2 Paclitaxel;Carboplatin
31 VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Unknown status NCT01666444 Phase 2 pegylated liposomal doxorubicin (PLD);VTX-2337;Placebo
32 Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
33 Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Unknown status NCT00003560 Phase 2 carboplatin;docetaxel
34 Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma Completed NCT00506779 Phase 1, Phase 2 Imatinib Mesylate;Paclitaxel
35 Papillary Serous Carcinoma of the Endometrium Completed NCT00515073 Phase 2 Paclitaxel;Dexamethasone;Cimetidine;Diphenhydramine
36 A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2 Carboplatin and Paclitaxel and Pelvic Radiation Therapy;Carboplatin and Paclitaxel and Radiation Therapy
37 Phase II ABT-888 With Cyclophosphamide Completed NCT01306032 Phase 2 ABT-888;Cyclophosphamide
38 Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer Completed NCT00022620 Phase 2 paclitaxel
39 Vargatef in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Ovarian Cancer Completed NCT01583322 Phase 2 vargatef;placebo
40 Uterine Papillary Serous Cancer (UPSC) Trial Completed NCT00147680 Phase 2 Paclitaxel, Carboplatin
41 A Phase II Trial of Adjuvant Radiation Therapy With Ifosfamide in Patients With MMT of the Uterus Completed NCT00231842 Phase 2 Ifosfamide
42 Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer Completed NCT01307631 Phase 2 Akt Inhibitor MK2206
43 Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01132820 Phase 2 Cediranib Maleate
44 Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer Completed NCT00052312 Phase 2 cisplatin;doxorubicin hydrochloride;paclitaxel
45 AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00275028 Phase 2 cediranib maleate
46 Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin Completed NCT00993616 Phase 2 belinostat;carboplatin
47 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00939809 Phase 2
48 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
49 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
50 Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00025467 Phase 2 thalidomide

Search NIH Clinical Center for Serous Cystadenocarcinoma

Cochrane evidence based reviews: cystadenocarcinoma, serous

Sources

Genetic Tests for Serous Cystadenocarcinoma

About this section
Sources

Anatomical Context for Serous Cystadenocarcinoma

About this section

MalaCards organs/tissues related to Serous Cystadenocarcinoma:

41
Ovary, Pancreas, Liver, Bone, Lymph Node, Uterus, Brain
Sources

Publications for Serous Cystadenocarcinoma

About this section

Articles related to Serous Cystadenocarcinoma:

(show top 50) (show all 106)
# Title Authors Year
1
Two protein-coding genes act as a novel clinical signature to predict prognosis in patients with ovarian serous cystadenocarcinoma. ( 29456732 )
2018
2
Serous cystadenocarcinoma of the spleen. ( 28491168 )
2017
3
High Grade Serous Cystadenocarcinoma of Testis-Case Report of a Rare Ovarian Epithelial Type Tumour. ( 28764180 )
2017
4
Expression of Yes-associated proteinA 1 and its clinical significance in ovarian serous cystadenocarcinoma. ( 28339095 )
2017
5
DNA methylation-regulated microRNA pathways in ovarian serous cystadenocarcinoma: A meta-analysis. ( 27746113 )
2016
6
Serous Cystadenocarcinoma Arising in Presumed Vitelline Duct Remnant: A Case Report and Implications in the Management of Cancer of Unknown Primary. ( 27999702 )
2016
7
Estimation of Prognostic Marker Genes by Public Microarray Data in Patients with Ovarian Serous Cystadenocarcinoma. ( 27189279 )
2016
8
A Five-Gene Expression Signature Predicts Clinical Outcome of Ovarian Serous Cystadenocarcinoma. ( 27478834 )
2016
9
Single nucleotide polymorphisms in glutathione S-transferase P1 and M1 genes and overall survival of patients with ovarian serous cystadenocarcinoma treated with chemotherapy. ( 27073511 )
2016
10
Serous Cystadenocarcinoma of the Pancreas: Clinical Features and Management of a Rare Tumor. ( 26998825 )
2016
11
Long-term survival of serous cystadenocarcinoma of the pancreas with synchronous liver metastases after aggressive surgical resection. ( 26177796 )
2015
12
Synchronous resection of pancreatic serous cystadenocarcinoma and liver metastasis: First reported case and review of literature. ( 26463518 )
2015
13
Solid variant type of serous cystadenocarcinoma of the pancreas: AA case report and review of the literature. ( 25716800 )
2015
14
Primary Peritoneal Papillary Serous Cystadenocarcinoma - A Rare Malignancy. ( 26713835 )
2015
15
"Sea anemone-like ciliated tumor cells" in a case of serous cystadenocarcinoma of the ovary. ( 26811576 )
2015
16
Serous cystadenocarcinoma of the mesentery in a man: case report and review of literature. ( 24759353 )
2014
17
Neoplasms in the trocar site and peritoneal papillary serous cystadenocarcinoma. ( 25017255 )
2014
18
Paratesticular papillary serous cystadenocarcinoma: A rare entity in Indian population. ( 25308020 )
2014
19
Ovarian serous cystadenocarcinoma metastasising to the breast. ( 23445161 )
2013
20
Histological percutaneous diagnosis of stage IV microcystic serous cystadenocarcinoma of the pancreas. ( 23370947 )
2013
21
IL-17A is elevated in sera of patients with poorly differentiated ovarian papillary serous cystadenocarcinoma. ( 24595078 )
2013
22
Serous cystadenocarcinoma of pancreas. ( 23763806 )
2013
23
Serous cystadenocarcinoma of the pancreas: report of a case and management reflections. ( 22400805 )
2012
24
Peritoneal papillary serous cystadenocarcinoma at a previous laparoscopic trocar site. ( 23040941 )
2012
25
Imaging of pancreatic serous cystadenocarcinoma. ( 22009426 )
2011
26
Testicular papillary serous cystadenocarcinoma: a rare case report and review of the literature. ( 22355499 )
2011
27
Pancreatic serous cystadenocarcinoma with invasive growth into the colon and spleen. ( 22066125 )
2011
28
Serous cystadenocarcinoma of the pancreas with portal thrombosis. ( 20499029 )
2010
29
Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade. ( 21266826 )
2010
30
Collision tumor: serous cystadenocarcinoma and dermoid cyst in the same ovary. ( 18818939 )
2009
31
Pancreatic serous cystadenocarcinoma: a case report and review of the literature. ( 19459016 )
2009
32
Papillary serous cystadenocarcinoma of the stomach, peritoneum and ovary. ( 20163045 )
2009
33
Serous cystadenocarcinoma of the ovary in an 11-year-old girl with extensive dissemination and chylothorax: a case report and a brief review of literature. ( 19564753 )
2009
34
Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma. ( 18574502 )
2008
35
Serous cystadenocarcinoma of the pancreas with metachronous hepatic metastasis. ( 19060596 )
2008
36
Macrocystic serous cystadenocarcinoma of the pancreas: the first report of a new pattern of pancreatic carcinoma. ( 18305183 )
2008
37
Plasma cell leukemia with ovarian serous cystadenocarcinoma. ( 17883177 )
2007
38
[Differential expression of USP2, USP14 and UBE4A between ovarian serous cystadenocarcinoma and adjacent normal tissues]. ( 17553343 )
2007
39
Immunohistochemical identification of primary peritoneal serous cystadenocarcinoma mimicking advanced colorectal carcinoma: a case report. ( 18036260 )
2007
40
[Oncogene ZNF217 amplification on chromosome 20 q in ovarian serous cystadenocarcinoma and its clinical implications]. ( 16793610 )
2006
41
Paratesticular papillary serous cystadenocarcinoma--a case report. ( 16625973 )
2006
42
[ZNF217 gene was detected in ovarian serous cystadenocarcinoma by fluorescence in situ hybridization]. ( 17160949 )
2006
43
Serous cystadenocarcinoma of the pancreas: management of a rare entity. ( 16025006 )
2005
44
Clinical significance of p21(WAF1/CIP1) and p53 expression in serous cystadenocarcinoma of the ovary. ( 16012716 )
2005
45
Serous cystadenocarcinoma of the pancreas. ( 15982220 )
2005
46
Primary papillary serous cystadenocarcinoma of broad ligament. ( 15845057 )
2005
47
A primary retroperitoneal serous cystadenocarcinoma with clinically aggressive behavior. ( 14551796 )
2004
48
Mean nuclear volume in ovarian papillary serous cystadenocarcinoma. ( 15032078 )
2004
49
Plasma cell leukaemia with papillary serous cystadenocarcinoma of ovary--a case report. ( 15025299 )
2003
50
Hepatic resection of metastatic tumor from serous cystadenocarcinoma of the ovary. ( 12068151 )
2002
Sources

Variations for Serous Cystadenocarcinoma

About this section
Sources

Expression for Serous Cystadenocarcinoma

About this section
Search GEO for disease gene expression data for Serous Cystadenocarcinoma.
Sources

Pathways for Serous Cystadenocarcinoma

About this section

Pathways related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 86)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 14.05 AKT1 B2M ERBB2 FBXW7 HRAS MMP2
2
GPCR Pathway 64
Show member pathways
 13.73 AKT1 ERBB2 ESR2 HRAS MMP2 PPP2R1A
3
HIV Life Cycle 66
Show member pathways
 13.72 AKT1 B2M ERBB2 FBXW7 HRAS MUC16
4
Developmental Biology 66
Show member pathways
 13.5 AKT1 ERBB2 HRAS MMP2 PIK3CA PPP2R1A
5
Class I MHC mediated antigen processing and presentation 66
Show member pathways
 13.48 AKT1 B2M ERBB2 FBXW7 HRAS PIK3CA
6
Cytokine Signaling in Immune system 66
Show member pathways
 13.32 AKT1 B2M ERBB2 HRAS MMP2 PIK3CA
7
Nanog in Mammalian ESC Pluripotency 64
Show member pathways
 13.28 AKT1 ERBB2 ESR2 HRAS PPP2R1A VEGFA
8
PI3K-Akt signaling pathway 37
Show member pathways
 12.98 AKT1 ERBB2 HRAS PIK3CA PPP2R1A TP53
9
Circadian entrainment 37
Show member pathways
 12.95 AKT1 ESR2 HRAS MMP2 PGR PIK3CA
10
Regulation of lipid metabolism Insulin signaling-generic cascades 22
Show member pathways
 12.92 AKT1 ERBB2 HRAS PIK3CA VEGFA
11
Focal Adhesion 37 1
Show member pathways
 12.91 AKT1 ERBB2 HRAS PIK3CA VEGFA
12
Endometrial cancer 37
Show member pathways
 12.9 AKT1 ERBB2 HRAS PIK3CA TP53 VEGFA
13
MAPK signaling pathway 1 37
12.79 AKT1 ERBB2 HRAS TP53 VEGFA
14
Development HGF signaling pathway 22
Show member pathways
 12.75 AKT1 ERBB2 HRAS PIK3CA TP53
15
Downstream signaling events of B Cell Receptor (BCR) 66
Show member pathways
 12.74 AKT1 ERBB2 HRAS PIK3CA PPP2R1A TP53
16
Gastric cancer 37
Show member pathways
 12.71 AKT1 ERBB2 ESR2 HRAS PGR PIK3CA
17
Development Endothelin-1/EDNRA signaling 22
Show member pathways
 12.68 AKT1 HRAS MMP14 MMP2 PIK3CA VEGFA
18
Kaposi's sarcoma-associated herpesvirus infection 37
Show member pathways
 12.62 AKT1 HRAS PIK3CA TP53 VEGFA
19
EPH-Ephrin signaling 66
Show member pathways
 12.61 HRAS MMP2 PIK3CA VEGFA
20
Immune response IL-23 signaling pathway 22
Show member pathways
 12.6 AKT1 ERBB2 HRAS MMP2 PIK3CA TP53
21
Immune response Fc epsilon RI pathway 22
Show member pathways
 12.59 AKT1 HRAS PIK3CA VEGFA
22
Development Dopamine D2 receptor transactivation of EGFR 22
Show member pathways
 12.58 AKT1 HRAS PIK3CA PPP2R1A
23
Pathways in cancer 37
12.58 AKT1 ERBB2 ESR2 HRAS MMP2 PIK3CA
24
MicroRNAs in cancer 37
12.56 ERBB2 HRAS PIK3CA TP53 VEGFA
25
Development EGFR signaling pathway 22
Show member pathways
 12.55 AKT1 ERBB2 HRAS MMP2 PIK3CA TP53
26
mTOR signaling pathway (KEGG) 65
Show member pathways
 12.54 AKT1 ERBB2 HRAS PIK3CA TP53
27
Prolactin Signaling Pathway 1 37
Show member pathways
 12.52 AKT1 ERBB2 ESR2 HRAS PIK3CA
28
Apoptosis Pathway 72
Show member pathways
 12.48 AKT1 ERBB2 HRAS PIK3CA TP53
29
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.46 AKT1 HRAS PIK3CA PPP2R1A TP53
30
ErbB signaling pathway 1 37
Show member pathways
 12.46 AKT1 ERBB2 HRAS PIK3CA TP53 VEGFA
31
HTLV-I infection 37
12.45 AKT1 HRAS PIK3CA TP53
32
VEGF Pathway (Qiagen) 64
Show member pathways
 12.43 AKT1 HRAS PIK3CA VEGFA
33
Development VEGF signaling via VEGFR2 - generic cascades 22
Show member pathways
 12.43 AKT1 HRAS PIK3CA VEGFA
34
Glioma 37
Show member pathways
 12.43 AKT1 ERBB2 ESR2 HRAS MMP2 PIK3CA
35
Oocyte meiosis 37
Show member pathways
 12.38 AKT1 PGR PIK3CA PPP2R1A
36
Signaling by ERBB2 66
Show member pathways
 12.35 AKT1 ERBB2 HRAS PIK3CA
37
Development Ligand-independent activation of ESR1 and ESR2 22
Show member pathways
 12.34 AKT1 ERBB2 ESR2 HRAS PIK3CA
38
G-protein signaling Ras family GTPases in kinase cascades (scheme) 22
Show member pathways
 12.26 AKT1 HRAS TP53 VEGFA
39
mTOR Pathway 72
Show member pathways
 12.22 AKT1 HRAS PIK3CA TP53
40
Cellular senescence (KEGG) 37
12.22 AKT1 HRAS PIK3CA TP53
41
Colorectal Cancer Metastasis 64
12.21 AKT1 MMP14 MMP2 TP53 VEGFA
42
Development EGFR signaling via small GTPases 22
Show member pathways
 12.19 AKT1 ERBB2 HRAS PIK3CA
43
Longevity regulating pathway 37
Show member pathways
 12.19 AKT1 HRAS PIK3CA TP53
44
AKT Signaling Pathway 67
12.19 AKT1 ERBB2 HRAS PIK3CA TP53
45
Transcription Androgen Receptor nuclear signaling 22
Show member pathways
 12.14 AKT1 ERBB2 HRAS MMP2 PIK3CA
46
Fluid shear stress and atherosclerosis 37
12.11 AKT1 MMP2 PIK3CA TP53 VEGFA
47
Development IGF-1 receptor signaling 22
Show member pathways
 12.1 AKT1 HRAS PIK3CA TP53
48
MAPK Pathway 72
Show member pathways
 12.09 AKT1 ERBB2 PIK3CA TP53
49
Hepatitis C 37
12.06 AKT1 HRAS PIK3CA PPP2R1A TP53
50
Thyroid hormone signaling pathway 37
12.04 AKT1 HRAS PIK3CA TP53
Sources

GO Terms for Serous Cystadenocarcinoma

About this section

Biological processes related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 angiogenesis GO:0001525 9.78 MMP14 MMP2 PIK3CA VEGFA
2 negative regulation of gene expression GO:0010629 9.76 AKT1 HRAS PGR VEGFA
3 negative regulation of cell growth GO:0030308 9.73 ESR2 PPP2R1A TP53
4 cellular response to hypoxia GO:0071456 9.72 AKT1 TP53 VEGFA
5 positive regulation of gene expression GO:0010628 9.72 AKT1 ERBB2 HRAS TP53 VEGFA
6 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.7 AKT1 PIK3CA VEGFA
7 positive regulation of cell growth GO:0030307 9.67 AKT1 ERBB2 MMP14
8 positive regulation of MAP kinase activity GO:0043406 9.61 ERBB2 HRAS VEGFA
9 positive regulation of epithelial cell proliferation GO:0050679 9.58 ERBB2 HRAS VEGFA
10 positive regulation of protein phosphorylation GO:0001934 9.56 AKT1 ERBB2 HRAS VEGFA
11 negative regulation of macroautophagy GO:0016242 9.54 AKT1 PIK3CA
12 epidermal growth factor receptor signaling pathway GO:0007173 9.54 AKT1 HRAS PIK3CA
13 anoikis GO:0043276 9.51 AKT1 PIK3CA
14 cytokine-mediated signaling pathway GO:0019221 9.35 AKT1 MMP2 PIK3CA TP53 VEGFA
15 ERBB2 signaling pathway GO:0038128 9.33 ERBB2 HRAS PIK3CA
16 phosphatidylinositol 3-kinase signaling GO:0014065 8.8 AKT1 ERBB2 PIK3CA

Molecular functions related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.86 AKT1 ALPP B2M ERBB2 ESR2 FBXW7
2 zinc ion binding GO:0008270 9.63 ALPP ESR2 MMP14 MMP2 PGR TP53
3 identical protein binding GO:0042802 9.23 AKT1 B2M ERBB2 ESR2 FBXW7 PGR
Sources

Sources for Serous Cystadenocarcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....